Aflibercept, a New Way to Target Angiogenesis in the Second Line Treatment of Metastatic Colorectal Cancer (mCRC)

Oxaliplatin and 5-FU/folinic acid (modified FOLFOX6) with or without aflibercept in first-line treatment of patients with metastatic colorectal cancer: the AFFIRM study

(2016) G. Folprecht et al.   ANNALS OF ONCOLOGY

Second-line angiogenesis inhibition in metastatic colorectal cancer patients: Straightforward or overcrowded?

(2016) Riccardo Giampieri et al.   CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY

Evaluation of efficacy and safety markers in a phase II study of metastatic colorectal cancer treated with aflibercept in the first-line setting

(2015) Diether Lambrechts et al.   BRITISH JOURNAL OF CANCER

Time course of safety and efficacy of aflibercept in combination with FOLFIRI in patients with metastatic colorectal cancer who progressed on previous oxaliplatin-based therapy

(2015) Paul Ruff et al.   EUROPEAN JOURNAL OF CANCER

Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study

(2015) Josep Tabernero et al.   LANCET ONCOLOGY

First-line chemotherapy for mCRC—a review and evidence-based algorithm

(2015) Chiara Cremolini et al.   Nature Reviews Clinical Oncology

Aflibercept Plus FOLFIRI vs. Placebo Plus FOLFIRI in Second-Line Metastatic Colorectal Cancer: a Post Hoc Analysis of Survival from the Phase III VELOUR Study Subsequent to Exclusion of Patients who had Recurrence During or Within 6 Months of Completing Adjuvant Oxaliplatin-Based Therapy

(2015) Eric Van Cutsem et al.   Targeted Oncology

Aflibercept in Combination with Folfiri in Patients with Metastatic Colorectal Cancer: Cost-Effectiveness Based on Velour Best Efficacy Subgroup Post-Hoc Analysis

(2015) M Echave et al.   VALUE IN HEALTH

Metastatic colorectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

(2014) E. Van Cutsem et al.   ANNALS OF ONCOLOGY

A VELOUR post hoc subset analysis: prognostic groups and treatment outcomes in patients with metastatic colorectal cancer treated with aflibercept and FOLFIRI

(2014) Ian Chau et al.   BMC CANCER

The “angiogenetic ladder”, step-wise angiogenesis inhibition in metastatic colorectal cancer

(2014) Riccardo Giampieri et al.   CANCER TREATMENT REVIEWS

Abstract B2: Switching to aflibercept treatment resulted in greater tumor responses than continuous bevacizumab treatment in patient-derived xenograft models of colorectal cancer.

(2014) M. Chiron et al.   MOLECULAR CANCER THERAPEUTICS

Differential Antitumor Activity of Aflibercept and Bevacizumab in Patient-Derived Xenograft Models of Colorectal Cancer

(2014) M. Chiron et al.   MOLECULAR CANCER THERAPEUTICS

Aflibercept

(2013) K. K. Ciombor et al.   CLINICAL CANCER RESEARCH

Cancer incidence and mortality patterns in Europe: Estimates for 40 countries in 2012

(2013) J. Ferlay et al.   EUROPEAN JOURNAL OF CANCER

Aflibercept versus placebo in combination with fluorouracil, leucovorin and irinotecan in the treatment of previously treated metastatic colorectal cancer: Prespecified subgroup analyses from the VELOUR trial

(2013) Josep Tabernero et al.   EUROPEAN JOURNAL OF CANCER

Vascular endothelial growth factor-dependent spatiotemporal dual roles of placental growth factor in modulation of angiogenesis and tumor growth

(2013) Xiaojuan Yang et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Aflibercept in the treatment of patients with metastatic colorectal cancer: latest findings and interpretations

(2013) Patricia A. Tang et al.   Therapeutic Advances in Gastroenterology

Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap, ranibizumab and bevacizumab

(2012) Nicholas Papadopoulos et al.   ANGIOGENESIS

Antiangiogenic Drugs for Colorectal Cancer: Exploring New Possibilities

(2012) Renata Ferrarotto et al.   Clinical Colorectal Cancer

Addition of Aflibercept to Fluorouracil, Leucovorin, and Irinotecan Improves Survival in a Phase III Randomized Trial in Patients With Metastatic Colorectal Cancer Previously Treated With an Oxaliplatin-Based Regimen

(2012) Eric Van Cutsem et al.   JOURNAL OF CLINICAL ONCOLOGY

Resistance and Escape From Antiangiogenesis Therapy: Clinical Implications and Future Strategies

(2012) Justin N. Bottsford-Miller et al.   JOURNAL OF CLINICAL ONCOLOGY

Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial

(2012) Jaafar Bennouna et al.   LANCET ONCOLOGY

Pharmacodynamic and pharmacogenetic angiogenesis-related markers of first-line FOLFOXIRI plus bevacizumab schedule in metastatic colorectal cancer

(2011) F Loupakis et al.   BRITISH JOURNAL OF CANCER

Phase II Trial of Infusional Fluorouracil, Irinotecan, and Bevacizumab for Metastatic Colorectal Cancer: Efficacy and Circulating Angiogenic Biomarkers Associated With Therapeutic Resistance

(2009) Scott Kopetz et al.   JOURNAL OF CLINICAL ONCOLOGY

Vascular Endothelial Growth Factor Mediated Decrease in Plasma Soluble Vascular Endothelial Growth Factor Receptor-2 Levels as a Surrogate Biomarker for Tumor Growth

(2008) J. M.L. Ebos et al.   CANCER RESEARCH